New bill aims to reform US patent system | PDF (145 KB)

p805 | doi:10.1038/nrd2168

HIV prevention trials in danger of grinding to a standstill | PDF (127 KB)

p806 | doi:10.1038/nrd2169

Origins of ecstasy an urban myth | PDF (91 KB)

p806 | doi:10.1038/nrd2172

Psychiatric disorders: ProTREKtion against depression | PDF (106 KB)

p817 | doi:10.1038/nrd2162

Angiogenesis: Familiar faces and new connections | PDF (67 KB)

p818 | doi:10.1038/nrd2160

Anticancer drugs: Activating the executioner | PDF (88 KB)

p818 | doi:10.1038/nrd2164

Biomarkers: Signatures of schizophrenia | PDF (84 KB)

p819 | doi:10.1038/nrd2161

Lung cancer: Strengthening the link to adenosine | PDF (98 KB)

p820 | doi:10.1038/nrd2163

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

Scott Wilhelm, Christopher Carter, Mark Lynch, Timothy Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov & Susan Kelley

p835 | doi:10.1038/nrd2130

In December 2005, sorafenib became the first new treatment to be approved for advanced renal cancer in more than a decade. Wilhelm and colleagues provide the history of this drug, which inhibits several kinases involved in tumour signalling and angiogenesis.

• Abstract
• Full Text
• PDF (679 KB)

Novel pharmacological targets for the treatment of Parkinson's disease

Anthony H. V. Schapira, Erwan Bezard, Jonathan Brotchie, Frédéric Calon, Graham L. Collingridge, Borris Ferger, Bastian Hengerer, Etienne Hirsch, Peter Jenner, Nicolas Le Novère, José A. Obeso, Michael A. Schwarzschild, Umberto Spampinato & Giora Davidai

p845 | doi:10.1038/nrd2087

Schapira and colleagues describe recent advances in the development of novel doperminergic and non-doperminergic drugs for the treatment of Parkinson's disease and related motor complications.

• Abstract
• Full Text
• PDF (655 KB)

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

Peter L. Bonate, Larry Arthaud, William R. Cantrell, Jr., Katherine Stephenson, John A. Secrist, III & Steve Weitman

p855 | doi:10.1038/nrd2055

Despite considerable progress in the treatment of paediatric leukaemias, a major need still exists for therapies for patients who relapse. Bonate and colleagues describe the discovery and development of the nucleoside analogue clofarabine, which is the first such drug approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use.

• Abstract
• Full Text
• PDF (549 KB)

Signalling platforms that modulate the inflammatory response: new targets for drug development

Christopher. A. McCulloch, Gregory P. Downey & Hani El-Gabalawy

p864 | doi:10.1038/nrd2109

Inflammatory diseases of lung, liver, heart, joints and periodontium have high prevalence, but many current treatments have limited efficacy and are expensive. McCulloch and colleagues consider new anti-inflammatory drug targets based on the clustering of interleukin- 1 receptors into multi-protein aggregates associated with cell adhesions.

• Abstract
• Full Text
• PDF (508 KB)